ARCA biopharma, Inc. logo

ARCA biopharma, Inc.

NASDAQ:ABIO

Overview | Financials
Company Name ARCA biopharma, Inc.
Symbol ABIO
Currency USD
Price 28.8
Market Cap 34,817,184
Dividend Yield 0%
52-week-range 2.247 - 53.88
Industry Biotechnology
Sector Healthcare
CEO Dr. Michael R. Bristow M.D., Ph.D.
Website https://www.arcabio.com

An error occurred while fetching data.

About ARCA biopharma, Inc.

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that

Related Stocks

vTv Therapeutics Inc. logo

vTv Therapeutics Inc.

VTVT

14 USD

T2 Biosystems, Inc. logo

T2 Biosystems, Inc.

TTOO

0.8 USD

Acer Therapeutics Inc. logo

Acer Therapeutics Inc.

ACER

0.9 USD

Immix Biopharma, Inc. logo

Immix Biopharma, Inc.

IMMX

1.58 USD

Avalo Therapeutics, Inc. logo

Avalo Therapeutics, Inc.

AVTX

13.54 USD

Financials

Numbers are in millions USD

Numbers are in millions USD